portant factors in proliferation and differentiation (5) . This cytokine overproduction causes inflammation, and a relationship has been determined with inflammatory and autoimmune diseases (6) . Significantly high serum IL-6 levels have been observed in patients with CD compared with healthy controls (5) . Genetic polymorphisms modifying IL-6 levels may therefore potentially be involved in susceptibility to CD. Dema et al. (7) determined that IL-6 (-174G/C) polymorphism increased the risk of CD in girls. However, another study determined no relation between this polymorphism and CD (2) . IL-6 (-572G/C) (rs1800796) is found adjacent to the IL-6 5' promoter region (8) . Previous studies have determined that this allele is responsible for high serum IL-6 levels and that polymorphism has an effect on the development of allergic rhinitis, osteoarthritis, and ischemic heart disease and on the prognosis of breast cancer (9) (10) (11) .
IL-17 is a proinflammatory cytokine expressed by T helper (Th) 17 cells, which creates an immune response to extracellular bacterial and fungal pathogens and plays a role in the development of inflammatory and autoimmune diseases (12) . The IL-17 cytokine family comprises six members, namely IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F (13) . Previous studies have compared treated and potential patients with CD and have reported IL-17 elevation in the mucosa of untreated patients (14, 15) . However, Ryan et al. (16) examined the relation between IL-17 polymorphisms and CD and showed no relation between IL-17 (762 C/A, 1586 A/G, and 6769 A/G) polymorphisms and CD. Espinoza et al. (17) showed that the IL-17A 197A allele correlates to more efficient IL-17 production. IL-17A (-197A/G) gene polymorphism has been shown to have an effect on the development of ulcerative colitis, gastric carcinogenesis, and acute myeloid leukemia (18) (19) (20) .
Polymorphisms in gene alignment have been found to have a significant effect on the production and/or functioning of cytokines (21) . Genetic polymorphisms have been reported to contribute to CD sensitivity by altering the levels and functions of cytokines (2) . This study aimed to evaluate IL-6 (-572G/C) (rs1800796) and IL-17 (-197A/G) (rs2275913) gene polymorphisms in children with CD. Further, we aimed to investigate the relationship between CD symptoms and histopathological findings and the relationship between these polymorphisms.
MATERIALS AND METHODS

Study Population
This prospective study involved patients with a diagnosis of CD for at least 1 year and no other known disease who were being followed-up. The patient group comprised 84 children, and the control group included 83 age-and gender-matched healthy children. The study was conducted in accordance with the principles of the Helsinki Declaration, and the ethics committee of Karadeniz Technical University School of Medicine granted the approval. Informed consent was obtained from patients and/or their parents or legal guardians. After receiving informed consent, 2 mL venous blood was collected from each participant in EDTA tubes. Diagnosis of CD was based on antitissue transglutaminase IgA (tTG-IgA) antibody positivity (>200 RU/mL) and typical histopathological findings after the evaluation of clinical symptoms.
Patients with CD were assigned into one of the two groups depending on their symptoms, classic or nonclassic. Classic symptoms were chronic diarrhea and/or abdominal distension and/or weight loss. Nonclassic symptoms included iron deficiency anemia not responding to treatment and of uncertain cause, short stature, dental enamel anomalies, elevated liver enzymes, cutaneous manifestations (dermatitis herpetiformis or recurrent oral aphthous ulcers), neurological manifestations (ataxia or peripheral neuropathy), and metabolic disorders (osteopenia/osteoporosis) (22) . The mucosal biopsy sections were subjected to analysis by an experienced histopathologist, and the diagnosis of CD was subsequently confirmed based on the modified Marsh-Oberhuber classification system (23) .
DNA Extraction and Genotyping
The presence of tTG-IgA antibody in serum was confirmed using the enzyme-linked immunosorbent assay (Euroimmun, Luebeck, Germany) method. DNA isolation was performed using an automatic Magna Pure Compact DNA isolation Device (Roche Diagnostics, Manheim, Germany). HLA-DQ2 and HLA-DQ8 allele genotyping was performed on Luminex technology (Gen-Probe LIFECODES, Stanford, CA) using the polymerase chain reaction (PCR) and sequence-specific oligonucleotide probe (PCRSSOP) hybridization method. For IL-17 (-197A/G) (rs2275913) polymorphism, F: 5' TTGACCCATAGCATAGCAGC 3', R: 5' GGGCTTTTCTCCTTCTGTGG 3' and for IL-6 (-572G/C) (rs1800796) polymorphism F: 5' GGCAATGGGGAGAGCACT 3', R: 5' GGGCTTTTCTCCTTCTGTGG 3' primary pairs were used, and the target areas were multiplied with PCR.
The BstENI enzyme was used for genotypic screening for IL-17A (-197A/G) and the FokI enzyme for IL-6 (-572G>C). PCR products were incubated for 16 h with restriction enzymes in the prepared reaction mixtures at 37°C with FokI enzymes and 37°C with the BstENI enzyme. Following the restriction reaction, the products were visualized with electrophoresis in 2.5% agarose gel.
Agarose gel was prepared following the treatment of PCR products with restriction enzymes. Subsequently, 5 μL was collected from treated products and mixed with 6 μL distilled water and 1 μL loading dye and then loaded into the gel wells. Analysis of the IL-6 (-572G/C) polymorphism revealed a higher level of the GG genotype in the patients with CD compared with the control group (p=0.018, odds ratio (OR): 5.47, 95% confidence interval (CI): 1.161-25.800). No statistically significant difference was determined between the groups in terms of allele frequency (Table 1) . No significant difference was determined between the groups with respect to genotype and allele frequency for IL-17 (-197A/G) polymorphism (Table 2) . No difference was determined between patients' histopathological findings and IL-6 (-572G/C) and IL-17 (-197A/G) polymorphisms in terms of genotype and allele frequencies (Table 3) . No difference was also determined between patients' symptoms and IL-6 (-572G/C) and IL-17 (-197A/G) polymorphisms in terms of genotype and allele frequencies (Table 4 ).
In post hoc power analysis, power was calculated as 53.93% between the patients with CD and control group for the IL-6 (-572G/C) polymorphism GG genotype.
DISCUSSION
Genetic factors are known to play a significant role in the development of CD. The most important risk factor for disease development is HLA grade II genes (24) . While 40%-90% of patients are HLA-DQ2-positive, fewer are HLA-DQ8 positive. Molecules related to immune system responses that are encoded in the genes have also been found to contribute to the development of CD (24) .
Mucosal damage in CD occurs with both a natural and an acquired immune response. Previous studies have shown that intestinal inflammation in CD is due to different cytokines produced by CD4 T cells and that these are responsible for the pathogenesis of the disease (5, 25) .
In addition to cytokines expressed by Th cells in the intestinal mucosa in CD, the production of macrophage-origin IL-6 has been determined to increase and play a role in intestinal inflammation (5, 25) . Studies have reported a relation between the IL-6 (-572G/C) polymorphism and high serum IL-6 (9). In comparison with the CC genotype, the IL-6 (-572G/C) G allele has been determined to be responsible for greater IL-6 production and higher serum level (26) . Fernandes et al. (10) reported that patients with the IL-6 (-572G/C) G allele had higher IL-6 levels than patients with the CC and CG genotypes, and the G allele was identified as a risk factor for the development of osteoarthritis. The relationship of this polymorphism with Type 2 diabetes was examined in a metaanalysis of 10 studies, which concluded that subjects with the GG genotype were at greater risk of developing the disease (27) . In the present study, which examined the relationship of the IL-6 (-572G/C) polymorphism with CD, the GG genotype was determined to be a risk factor for disease development. However, we determined no association between the IL-6 (-572G/C) polymorphism and the histopathology (Marsh grade). Although Kapoor et al. (5) reported that IL-6 values were significantly increased in CD and proved to be a reliable marker for disease activity, a poor correlation was noted with the histopathology (Marsh grade). This study has some limitations. The study population was relatively small, and we cannot generalize our results to other populations with heterogeneous ethnical composition. In addition to the effect of IL-6 (-572G/C) and IL-17A (-197 G/A) polymorphisms on gene transcription were not investigated.
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In conclusion, the results of this study show a significant relation between the IL-6 (-572G/C) (rs1800796) polymorphism and CD. The presence of allele G in the IL-6 gene polymorphism (-572G/C) may be regarded as a risk factor for the development of CD. This suggests that the IL-6 (-572G/C) polymorphism should be evaluated as a risk factor in the development of CD.
Further studies with higher patient numbers are now needed to confirm the relationship between this polymorphism and CD. 
